Sun Pharma bucks the trend
India’s largest pharma company has caught investors’ fancy and a lot of it is due to founder Dilip Shanghvi’s need to take a different path.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
Why everyone’s going gaga over weight-loss drugs
To shed pounds fast, Indians are going to great lengths to secure weight-loss drugs from abroad. Soon, they may not have to look elsewhere as US drugmaker Eli Lilly gets early approvals in India for its new weight-loss drug.
